Previous 10 | Next 10 |
Summary Halvorsen's 13F portfolio value decreased marginally from $21.86B to $21.66B this quarter. The number of positions increased from 82 to 88. Viking Global increased Elevance Health, Visa, and McKesson while decreasing T-Mobile US, Parker Hannifin, and Fortive. They also dropped A...
Humanigen ( NASDAQ: HGEN ) has agreed to pay Catalent Pharma Soutions ( NYSE: CTLT ) to resolve a supply agreement dispute over the biologic lenzilumab . Lenzilumab is under development by Humanigen for chronic myelomonocytic leukemia. Seeking Alpha's Quant Ratin...
Summary The Seeking Alpha Quant system has its quirks, but it is a great tool to find holdings. I will discuss the performance of the five holdings I covered in the prior article. Also, at the end, I will provide some interesting literature discussing the Seeking Alpha platform as a...
Board of Directors Selects J. Martin Carroll as Next Chair Executive Chair John Chiminski and Directors Rolf Classon and Peter Zippelius to Retire Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, la...
Catalent Inc. ( NYSE: CTLT ) dropped 4.9% following a short report from Glasshouse Research. Glasshouse sees "material headwinds" for the pharmaceutical contract manufacturer going forward, leading the firm to give CTLT a "strong sell" recommendation. Catalent ( CTL...
Shares of Catalent (NYSE: CTLT) , which provides delivery and development solutions for healthcare companies, fell 36% this week, according to data from S&P Global Intelligence . The stock closed last week at $66.18 then opened on Monday at $65.76. The stock hit its 52-week low ...
— New priority discovery programs focused on three oncology targets with potential to develop antibody-drug conjugates (ADCs) for a variety of solid tumor indications — Exelixis, Inc. (Nasdaq: EXEL) and Catalent, Inc. (NYSE: CTLT) today announce...
BofA Securities has downgraded Catalent ( NYSE: CTLT ) to neutral from buy after the company cut its fiscal 2023 organic growth target. The firm also cut its price target to $60 from $125 (~21% upside based on Tuesday's close). Analyst Derik de Bruin said that increasi...
Summary Having suffered through a sharp decline in earnings multiples, SMID cap growth stocks held up well in a volatile quarter marked by a sharp upward ratcheting of interest rates. The Strategy underperformed its benchmark, primarily due to weakness among health care holdings t...
Specialty healthcare-company Catalent (NYSE: CTLT) was looking anything but special to investors on Tuesday. Its share price saw a queasy drop of nearly 25% on the day, following the release of dispiriting quarterly results. For its first quarter of fiscal 2023, Catalent booked ...
News, Short Squeeze, Breakout and More Instantly...
Expansion adds more temperature-controlled storage and dedicated space for FastChain ® demand-led supply service Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansio...
2024-06-30 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 07:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for CTLT on June 28, 2024 05:28AM ET. The previous analyst recommendation was Equal-Weight. CTLT was trading at $56.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...